ClascoteroneClascoterone
MedChemExpress (MCE)
HY-13331
19608-29-8
Cortexolone 17 alpha-propionate
Cortexolone 17α-propionate
CB-03-01
98.76%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Room temperature in continental US
may vary elsewhere.
Clascoterone (Cortexolone 17 alpha-propionate
Cortexolone 17α-propionate
CB-03-01) is a new topical and peripherally selective androgen antagonist.
Clascoterone is a new potent topical antiandrogen potentially useful in acne vulgaris. Clascoterone 1% cream was very well tolerated, and was significantly better than placebo regarding TLC (P = 0·0017), ILC (P = 0·0134) and ASI (P = 0·0090), and also clinically more effective than comparator. The product also induced a faster attainment of 50% improvement in all the above parameters.
Androgen Receptor[1]. In Vivo Clascoterone is a new potent topical antiandrogen potentially useful in acne vulgaris. Clascoterone 1% cream was very well tolerated, and was significantly better than placebo regarding TLC (P = 0·0017), ILC (P = 0·0134) and ASI (P = 0·0090), and also clinically more effective than comparator. The product also induced a faster attainment of 50% improvement in all the above parameters. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| | | |
| | | | | |
[1]. Trifu V, et al. Cortexolone 17伪-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0路05% cream. Br J Dermatol. 2011 Jul
165(1):177-83. [Content Brief]
[2]. Trifu V, et al. Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream. Br J Dermatol. 2011 Jul
165(1):177-83.
[3]. Celasco G, et al. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004
54(12):881-6. [Content Brief]